Faculty: Alexis Te, MD and Matthew Rutman, MD
Moderator: John Wei, MD
Alexis E. Te, MD
Dr. Alexis E. Te is a Professor of Urology at the Weill Medical College at Cornell University and Director of the Brady Prostate Center and the Urology Program of the Iris Cantor Men’s Health Center in Department of Urology at New York Presbyterian Hospital. Dr. Te graduated from Yale University and received his medical degree from Cornell University Medical College. He completed his urology residency and fellowship in Neurourology and Urodynamics at the College of Physicians and Surgeons of Columbia University.
Dr. Te is a national and international key opinion leader on minimally invasive BPH therapies including using the 532 nm wavelength or Greenlight Laser for benign prostate surgery, and is active in numerous clinical trials for BPH therapies. Dr. Te is active lecturer and clinician, honored annually as a top clinician in Castle Connelly, Best Doctors and Superdocs. He is also active reviewer and has been on editorial board of numerous journals, and has over 300 publications. Dr. Te’s main areas of academic interest and research include Prostate Disease including BPH, chronic prostatitis and prostate cancer as well as voiding dysfunction, urodynamics, neurourology, incontinence and female urology. As an innovator in medical technology, Dr. Te has patents in medical applications.
Matthew Rutman, MD
Matthew Rutman, M.D., Associate Professor of Urology at CUMC, is the Director of Voiding Dysfunction, Incontinence and Female Urology at Columbia University Medical Center. He is the Director of the Female Urology and Voiding Dysfunction Fellowship. He graduated with honors from Emory University and The Chicago Medical School. After completing his residency at William Beaumont Hospital, Dr. Rutman completed a fellowship in female urology, voiding dysfunction, neurourology and urodynamics under world renowned Shlomo Raz, M.D at the UCLA Medical Center.
Dr. Rutman is board-certified in Urology and Female Pelvic Medicine and Reconstructive Surgery (FPMRS). His practice is limited to male and female voiding dysfunctions including urinary retention, benign prostatic hyperplasia (BPH), interstitial cystitis, prostatitis, urinary incontinence, overactive bladder, neurogenic bladder, urinary tract infections, and reconstructive female urology surgery for vaginal prolapse, urethral diverticulum and vesico-vaginal fistulae. He has authored over 40 book chapters and publications in leading journals and urology textbooks. His clinical and research interests are in male and female incontinence, vaginal prolapse, voiding dysfunction, urodynamics and surgical outcomes.
John Wei, MD
John T. Wei, MD, MS, Professor of Urology and the Associate Chair for Faculty Affairs and Communications in the Department of Urology at Michigan Medicine, Ann Arbor, MI, graduated from the Medical Education 6-year BS-MD Honors Program at Northwestern University, Evanston, IL and completed his urology training at the New York Hospital–Cornell Medical Center in New York City in 1997. Dr. Wei received both the Deans Excellence in Mentoring Award and the Deans Clinical and Health Services Research Award from the University of Michigan in 2013. He was inducted into the American Association of Genitourinary Surgeons in 2014.
Dr. Wei recently became the Medical Director for the Brighton Center for Specialty Care in 2018. This multi-specialty medical care facility based in Brighton, Michigan is an extension of Michigan Medicine.
Dr. Wei devotes 50% of his time to education/research with the remainder spent involved with clinical patient care. He has led the prostate cancer detection and Benign Prostatic Hyperplasia (BPH) research programs in the University of Michigan Urology Department (UM-Uro).
His clinical focus includes the evaluation and treatment of male BPH, Prostate Cancer Biomarkers, and Quality of Life outcomes. Using the RAND prostate cancer quality indicators, the quality of care for localized prostate cancer was evaluated using a national cohort (the American College of Surgeons national cancer database). To date, the UM-Uro has developed novel measures for early stage prostate cancer (EPIC), urinary incontinence (M-ISI), and adaptation to pelvic floor disorders (ABI).
His primary research focuses on the development and validation of health related quality of life measures, and the evaluation of quality of care for urologic conditions with an overarching goal to improve the delivery of urologic care. His other research interests also include biomarker validation where his research was funded by the Early Detection Research Network (EDRN). Currently, Dr. Wei is the site PI for the Clinical Epidemiology Validation Center and the study chair for the PCA3 Validation trial.
As the PI of the T32 fellowship-training program, Dr. Wei utilizes the academic environment for the opportunities to work closely with and mentor junior urologists, and medical students who have an interest in pursuing a career in academic and clinical urologic research fields.
Dr. Wei’s general urology clinical practice continues with a focus on male voiding problems BPH and prostate cancer early detection (i.e., men with elevated PSA).